• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding

    The Baseline

    12
    Following
    368
    Stocks Tracked
    49
    Sectors & Interests
    Follow
    Load latest
    logo
    The Baseline
    26 Feb 2025
    Nifty Midcap is the winner among indices. But it's not without risks | Screener: Stocks that outperformed Q3, with strong estimates for next quarter

    Nifty Midcap is the winner among indices. But it's not without risks | Screener: Stocks that outperformed Q3, with strong estimates for next quarter

    By Tejas MD

    The Indian stock market has been caught in a bear hug. The Nifty 50 is set to post losses for the fifth straight month—a trend we haven't seen since 1996. Unlike previous sharp corrections though, this downturn has been a slow bleed, with red ink drip-dripping across the charts every month.

    Just six months ago, the mood was very different. Markets were hitting record highs. It seemed like stocks could only go up.

    A mix of heavy FII selling, earnings downgrades, and global uncertainty, especially from the US, sent the market into reverse. If you poured in money during the highs, well, let’s just say that it hasn’t been the most rewarding stretch.

    As the joke goes, "Everyone becomes a long-term investor in a falling market."

    So with this extended correction, have valuations finally become attractive, or are stocks still overpriced?

    To get a clearer picture, we turned to Trendlyne’s Historical PE Analysis tool to see where things stand for the Nifty 50, Nifty Midcap 100, and Nifty Smallcap 100.

    Let’s dive in.

    In this week’s Analyticks, 

    • Valuation check: The benchmark Nifty 50 index turns attractive 
    • Screener: Stocks which beat Q3 Forecaster estimates for revenue and net profit with high revenue and EPS growth expectations for Q4FY25

    Nifty Midcap 100 wins in the long run, but there are risks

    The recent market correction has dragged the major indices down from their peaks. The Nifty 50 and Nifty Midcap 100 have entered the correction zone after falling over 10% from their highs, and the Nifty Smallcap 100 has crossed the 20% loss mark (bear market territory). 

    Nifty Midcap 100 outperforms peers in long term gains

    Despite these short-term setbacks, the Nifty Midcap 100 has proven its strength over the long run, outperforming both the Nifty 50 and the Nifty Smallcap 100. But this impressive performance comes with heightened valuation risks.

    Sankaran Naren, Chief Investment Officer of ICICI Prudential Mutual Fund, said in an event on February 12, “India has one of the best macros in the world compared to other countries, but our smallcap and midcap valuations are absolutely absurd right now”. He asked investors to pause their SIP in the current environment.  

    However on Monday, Citigroup upgraded its rating on Indian stocks from ‘neutral’ to ‘overweight’, pointing to improving consumer sentiment, expected rate cuts, and minimal exposure to US trade risk.

    Midcaps shine, but earnings struggle

    The Nifty Midcap 100 has historically commanded a higher price-to-earnings (PE) ratio, due to the stronger growth potential of its companies, which are seen as mid-sized and fast-growing. At 33.9, it has the highest PE among the three major indices.

    But this elevated PE is also due to a sharp drop in its earnings per share (EPS) in Q4FY24.

    Nifty 50 PE falls 12.2% in the past year, while Nifty Midcap 100 PE surges 33.2%

    The Q3FY25 results did not help the Nifty Midcap’s EPS recover to the March 2024 level. Companies like Oil India (Oil and gas), Petronet LNG (Oil and gas), and Oracle Financial Services (Software and services) reported sharp falls in their EPS. As a result, the Nifty Midcap continues to trade at a high PE.

    Analysts see Nifty 50 as the most promising, backed by historical data

    Like the Nifty Midcap, the Nifty Smallcap 100 is also trading at a premium compared to its 10-year average. Nifty Midcap 100 and Smallcap 100 both beat the Nifty 50 in revenue growth - they posted a Q3FY25 revenue growth of 8.2% and 8.7%, outpacing Nifty 50’s 4.5% increase. 

    But indices with high PE ratios are more vulnerable to market downturns, as seen in the past quarter. The Nifty Midcap 100 and Nifty Smallcap 100 both suffered steeper losses than the Nifty 50.

    In comparison, the Nifty 50 appears more reasonably valued. Its current PE is below its historical averages, and its forward PE of 19 makes it even more appealing.

    Buy zone?: 1 year forward PE of indices below current PE

    Beating the bears: Midcaps dominate the list of top performers

    The top-performing midcap companies have held on to their gains over the past year, even as the broader market has faced turbulence.

    In contrast, smallcap stocks have taken a big hit since the correction began, wiping out the triple-digit returns that once dominated the Nifty Smallcap 100. This has especially hurt large investors who specialize in smallcaps, like Ashish Kacholia.

    Top performers in Nifty Midcap 100 outperform large and Smallcap cos

    Midcaps have emerged as clear winners, with all the top five stock market performers in the Nifty Midcap 100. In the Nifty 50, the auto sector has stood out, with Mahindra & Mahindra and Eicher Motors securing two of the top five spots. 

    Foreign institutional investors (FIIs) have been selective in their bets. Only five companies across the three indices saw FII holdings increase by over 3% in Q3FY25: IDFC First Bank, Voltas, BSE, PNB Housing, CDSL, and Chambal Fertilisers. And none of these companies are in the Nifty 50.

    Worst-performing stocks: some investors are feeling the pain

    The Nifty Smallcap 100 has struggled in the past year, with only 43% of its stocks delivering gains. The Nifty Midcap 100 and Nifty 50 have fared slightly better, with 53% and 50% winner-to-loser ratios, respectively.

    Four companies across the three indices have lost nearly half their value. Hopefully, none of your portfolio picks are on this list—Mangalore Refineries (falling profits), Vodafone Idea (loss-making), Sterling and Wilson (PE of 234), Tanla Platforms (falling profits) and Sonata Software(falling margins).

    Five companies in the Nifty Smallcap 100 lose nearly half their value in the past year

    In the Nifty 50, Adani Enterprises takes the unwanted top spot as the worst performer, shedding a third of its value over the past year.

    The market correction has affected all the major indices. While midcaps have outperformed over the long term, their high valuations and recent earnings struggles raise concerns. Large caps appear more reasonably valued and could offer a safer bet amid market uncertainty. 

    But foreign brokerages like Citi and Jefferies are turning bullish on Indian markets, citing Nifty 50's attractive valuation at 19x forward earnings, which is below its historical averages.

    Looking ahead, factors like good Q4 earnings, rate cuts and FII interest could provide some support. But the red flags of elevated valuations in mid and small-cap stocks are still there. 


    Screener: Stocks which beat Q3 Forecaster estimates for revenue and net profit with high revenue and EPS growth expectations for Q4FY25

    Stocks beating Forecaster estimates are from diverse sectors

    With the end of the Q3FY25 results season, we look at stocks that outperformed expectations during the quarter, that also have high growth estimates for Q4FY25. This screener shows stocks which beat Trendlyne's Forecaster estimates for revenue and net profit in Q3FY25, with high revenue and EPS YoY growth expectations for Q4FY25.

    The screener consists of stocks from the aerospace & defence, cement & cement products, commercial vehicles, consumer electronics, IT consulting & software, and pharmaceuticals industries. Interesting stocks in the screener are Bharat Electronics, Ambuja Cements, Indian Hotels Company, Ashok Leyland, Blue Star, APL Apollo Tubes, Bajaj Finance, and Bharti Airtel.

    Bharat Electronics features in the screener after beating Forecaster estimates for revenue and net profit by 17.4% and 37.3%, respectively, in Q3FY25. This aerospace & defence stock’s revenue and net profit grew 37.6% YoY and 52.5% YoY, respectively. Revenue growth was supported by a strong order book of Rs 71,100 crore and an order inflow of Rs 11,000 crore during 9MFY25.

    Analysts at Motilal Oswal expect the company’s revenue to surge on the back of large-sized order inflows from quick reaction surface-to-air missile (QRSAM) and next-generation corvettes. However, the focus will shift to order execution. Any delays can hurt the company’s top and bottom line. 

    Indian Hotels’ Q3FY25 revenue and net profit beat forecaster estimates by 4.3% and 1.1%, respectively. This hotels stock’s revenue increased by 29.4% YoY, driven by an improvement in the food & beverage and new business segments, rising average room rate (ARR), and occupancy.

    Its net profit jumped by 28.9% YoY, led by improving margins in the new business segment and a recovery in US subsidiaries. Axis Direct expects the company’s revenue and net profit to grow on the back of a low supply of rooms and an increase in Foreign Tourist Arrivals (FTAs), which positively impact ARRs.

    You can find more screeners here.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    26 Feb 2025

    Chart of the Week: FIIs hit the brakes, shift into reverse

    By Abdullah Shah

    2024 witnessed a slew of global conflicts, sticky inflation, and high interest rates, resulting in Foreign Institutional Investors (FIIs) getting a lot pickier with their investments in the Indian equity market. Investments and withdrawals were sector-specific investments and withdrawals. 

    The trend persists in 2025 as Trump has been known to make both friends and enemies easily, and he brings this penchant into geopolitics. Markets have reacted sharply to his tariffs against allies and his outreach to Putin. 

    Since January 2024, FIIs have sold total equities worth Rs 77,597 crore. FII shareholding in Indian equities were at a 12-year low of 16% in January 2025.

    Speaking on the FII sell-off, Finance Minister Nirmala Sitharaman said, “FIIs go out when they are in a position to book profits. The Indian economy has an environment today where investments are yielding good results and profit-booking is happening.” 

    Sitharaman is dodging a bit here. Profit booking isn’t the only factor driving FIIs to sell. Concerns such as earnings downgrades, a weakening rupee, slower-than-expected GDP growth, and anemic private capital expenditure are also fueling the outflows.

    This Chart of the Week dives into the patterns of FII investments across various sectors in the past several months.

    FIIs trim holdings in Finance, Oil & Gas, and IT stocks 

    The financial sector bore the brunt of FII sell-offs in 2024 and January 2025. FIIs offloaded financial sector shares worth Rs 83,229 crore since January 2024, with January and October 2024 witnessing the highest outflows of Rs 30,013 crore and Rs 26,139 crore, respectively. 

    After four consecutive years of healthy double-digit growth, Indian equities faced earnings downgrades in the past two quarters. 

    The Indian government's estimates for GDP in FY25 confirmed the vibes – that the economy is seeing a slowdown. Real GDP growth is estimated to decelerate to 6.4% from 8.2% in FY24. This is below both the Ministry of Finance's forecast of 6.5% and the Reserve Bank of India's projection of 6.6%. 

    The Indian rupee also weakened to a record low of Rs 87.2 against the US dollar in January 2025, after the RBI stopped aggressively defending the rupee via dollar sales. This depreciation has increased currency risk for FIIs, potentially triggering further outflows as investors sought to limit foreign exchange losses. 

    Dr. V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services, noted, "Despite the massive FPI selling in financials, this sector is resilient since the valuations are fair and every selling is being absorbed by Domestic Institutional Investors (DIIs) and individual investors, particularly HNIs." 

    The oil & gas sector also saw substantial FII exits, with total sell-offs amounting to Rs 57,912 crore by January 2025. Notably, October, November, and December 2024 alone accounted for Rs 45,616 crore of these outflows. 

    Fluctuating global oil prices from geopolitical tensions and supply-demand imbalances from US sanctions on Russian crude oil, have created uncertainty in the sector. FIIs further lost confidence in the sector due to domestic policy adjustments, including changes in subsidies and taxation.

    The oil & gas marketing industry’s revenue and net profit declined by 3.8% YoY and 65.8% YoY during Q3FY25, further contributing to the sell-off. With the sector weakening, BPCL fell out of the Nifty 50 index in the most recent reshuffle.

    The IT sector presents a mixed picture. While specific periods saw FII interest, the overall trend  indicates caution. In January 2025, FIIs withdrew approximately Rs 6,471 crore from IT stocks, reversing the Rs 14,566 crore invested in November and December 2024. Signs of a potential slowdown in key markets such as the US, have investors anticipating reduced demand for IT services.

    High valuations in the IT sector and earnings downgrades prompted FIIs to book profits. Aamar Deo Singh, Senior Vice President of equity, commodity, and currency at Angel One, referred to this as a "double whammy," as the dip in consumer sentiment follows higher-than-expected January inflation figures of 3% compared to 2.9% in December. 

    Consumer Services and Capital Goods sectors see limited FII interest

    FIIs showed mixed interest in sectors like consumer services and capital goods. While these sectors saw good FII activity, the investments were modest. The sectors saw FII investment in H1CY24. However, investor interest declined towards the end of 2024 and January 2025.  

    Despite the Union Budget's focus on boosting discretionary spending, concerns over stretched valuations and a slowing trend in urban consumption led to profit-booking by foreign investors. A continued recovery in demand is needed for investors to return.

    Healthcare and Realty sectors attract FIIs, backed by favourable government regulations

    As a defensive sector, the healthcare sector attracted FII investments with inflows of Rs 23,984 since January 2024. The sector also witnessed FIIs investing Rs 20,823 crore from June to September 2024 after expectations of increased spending. India's healthcare sector continued to expand, with growing demand for hospital chains, specialized treatments, and innovative drug research. Government initiatives to improve healthcare services made the sector attractive to foreign investors.

    The realty sector saw a surge in foreign institutional investments of Rs 5,375 crore, Rs 2,061 crore and Rs 4,778 crore in September, November, and December 2024. This suggests growing confidence in India's real estate market. Rapid urbanization and government initiatives aimed at infrastructure development have strengthened the realty sector's prospects. 

    Overall, 2024 witnessed significant FII outflows, with financials and oil & gas sectors facing the largest withdrawals. So far, 2025 has seen a similar trend. However, the healthcare and real estate sectors have attracted foreign investments – investors are lifting some boats over others

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    25 Feb 2025
    Five stocks to buy from analysts this week - February 25, 2025

    Five stocks to buy from analysts this week - February 25, 2025

    By Ruchir Sankhla

    1. Nazara Technologies:

    ICICI Securities maintains a ‘Buy’ rating on this internet software company with a target price of Rs 1,080. This indicates an upside potential of 16.9%. Analysts Abhisek Banerjee and Jayram Shetty highlight its strong growth potential, supported by recent acquisitions, business expansion, and a solid market position in gaming, eSports, and ad-tech.

    The company is expanding through acquisitions, including a 60% stake in indoor play center Funky Monkeys for Rs 43.7 crore, marking its entry into the physical entertainment gaming segment. It also acquired CATS: Crash Arena and King of Thieves from ZeptoLab for Rs 65.5 crore, strengthening its mobile gaming portfolio. Additionally, its eSports subsidiary, Nodwin Gaming, acquired esports events business StarLadder for Rs 46.8 crore, enhancing its global eSports leadership.

    Banerjee and Shetty note that the investor interest remains strong, with Axana Estates investing ~Rs 495 crore for a 5.4% stake, alongside a public offer for an additional 26%. Management targets Rs 300 crore EBITDA by FY27, driven by scaling up its content library and expanding partnerships with game developers and publishers.

    2. Marico:

    Sharekhan retains its ‘Buy’ rating on this consumer goods manufacturer with a target price of Rs 780, indicating a potential upside of 25.4%. The company’s Q3FY25 revenue rose 15.4% YoY to Rs 2,794 crore due to growth in core categories such as coconut oil, hair oils, and premium refined edible oils, along with contributions from new business expansion, while its net profit increased 4.2% YoY to Rs 399 crore.

    The analysts note that the domestic volume grew 6%, improving from 5% in Q2 and 4% in Q1. International sales rose 16%, driven by 20% growth in Bangladesh, 35% in the Middle East and North Africa, and 17% in South Africa. Operating profit rose, but operating margin fell 210 bps YoY to 19.1% due to higher copra and vegetable oil prices.

    The company’s management believes that the consistent growth in the core portfolio, driven by brands like Parachute and Saffola, and over 20% growth in the foods and premium personal care portfolio, led by Saffola Oats, True Elements, Plix and Beardo. Additionally, a double-digit growth in the international business will help revenue expansion in the medium term. Analysts are optimistic about the company and expect a CAGR of 11.9% in revenue and 15.1% in net profit over FY25-27.

    3. Federal Bank:

    Emkay retains its ‘Buy’ rating on this bank with a target price of Rs 240, indicating an upside potential of 34.3%. Analysts Anand Dama and Nikhil Vaishnav highlight the bank’s efforts under new MD & CEO KVS Manian to strengthen its core and become a top private bank.

    Dama and Vaishnav note that the bank has built a strong digital and physical network, a diverse loan portfolio, and stable leadership. The bank now aims to improve profitability with a return on assets (RoA) of 1.4-2.3% over the next 3-4 years and join top private banks like ICICI Bank and HDFC Bank. To achieve this, it is focusing on improving margins and asset quality.

    Recently, the bank has taken steps such as deliberately slowing growth to manage liquidity and asset quality risks, increasing provisions for bad loans, and shifting auto loans to fixed rates to handle interest rate changes better. It plans to improve its CASA (current and savings account) ratio to 36% from 30% by FY28 by expanding in Tier-2 cities, attracting non-resident deposits, and offering wealth management services. 

    4. Indus Towers:

    Ventura initiates coverage on this telecom infrastructure company with a ‘Buy’ rating and a target price of Rs 450. This indicates a potential upside of 35.7%. The company’s net profit surged 2.6X YoY to Rs 4,003 crore in Q3FY25. This increase was mainly after Indus reversed a Rs 3,020 crore provision (previously set aside for doubtful payments from Vodafone Idea), bringing the total pending amount down to Rs 500 crore. Additionally, the company raised Rs 1,910 crore in Q3 by selling a pledged 3% stake held by Vodafone PLC.

    The analysts highlight that 5G rollouts are driving demand for towers and co-locations. In Q3, Indus Towers added 4,985 macro towers and 7,583 co-locations. They note that growing 5G adoption will require more infrastructure to manage increasing traffic. Indus Towers is expanding its In-Building Solutions (IBS) portfolio, with small cell deployment in malls, airports, and stadiums to improve indoor coverage and network capacity.

    The analysts expect the company’s tenancy ratio (average tenants per tower) to increase from the current 1.65X to 1.7X by FY27.

    5. Ethos:

    Axis Securities maintains a ‘Buy’ rating on this specialty retail firm with a target price of Rs 3,070, indicating a potential upside of 20.7%. A retailer of luxury watches and accessories, Ethos added five new stores in Q3FY25, bringing the total count to 73. The company’s management stated that it remains committed to expansion and aims to open six more boutiques by the end of FY25.

    Ethos reported a 32% YoY revenue growth in Q3, reaching Rs 376 crore. EBITDA margins stood at 15.4%, down 42 bps, impacted by higher costs from hiring staff for new stores and rent for recently opened stores that are still in their early sales phase.

    Analysts Preeyam Tolia and Suhanee Shome project the company's revenue to grow at a 34.5% CAGR over FY25-27, driven by a higher share of high-margin exclusive brands and expansion into luxury segments like luggage and jewellery. The company’s management aims for 10x revenue growth over the next decade.

    Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

    (You can find all analyst picks here)

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    21 Feb 2025
    Five Interesting Stocks Today - February 21, 2025

    Five Interesting Stocks Today - February 21, 2025

    By Trendlyne Analysis

    1. Narayana Hrudayalaya:

    Thishealthcare facilities company surged 3.1% on February 18 following the announcement of itsQ3FY25 results. During the quarter, the company’s revenue rose 13.6% YoY to Rs 1,366.7 crore. Its net profit grew 2.6% YoY to Rs 192.9 crore, beating theForecaster estimates by 6.6%. 

    The growth was driven by better realizations, with an Average Revenue Per Occupied Bed (ARPOB)growth of 9% YoY, and increased domestic patient footfalls. However, international patient volumes declined by 51% YoY and 48% QoQ, primarilydue to a drop in patients from Bangladesh amid geopolitical issues.

    In Q3FY25, revenue from the Cayman Islandsrose 14% YoY, accounting for 21% of total sales. Growth was driven by strong outpatient demand at the new Camana Bay hospital. Inpatient department operations began in January 2025, with full operationalization expected by Q4FY25.

    Sandhya J, Group Chief Financial Officer of the companysaid, “We are entering a capex growth phase right now, and are going to add at least 1,400 beds in the next 3 to 4 years.” The company plans toexpand further, adding about 2,000 beds over six years.

    To support this expansion, the company has allocated acapex of Rs 1,650 crore in FY25, Rs 1,000 crore in FY26, and Rs 850 crore in FY27. Key projects driving this expansion include new hospitals in Bangalore and Kolkata, a 300-bed expansion in Raipur, and a 220-bed facility in Central Bangalore. Additionally, the company isexploring expansion opportunities in existing locations and aims for returns of over 15%. 

    Post results, Prabhudas Lilladhermaintained its ‘Buy’ rating on the company, citing its aggressive expansion plans and strong financial performance, including a 10% YoY increase in EBITDA and 9% YoY ARPOB growth in India. The brokerage also highlights operational efficiencies, improved margins in new India units, and the anticipated ramp-up of the Cayman unit as key factors supporting its recommendation, with a target price of Rs 1,560.

    2. Muthoot Finance:

    This gold loan NBFC surged by 6.2% on February 13 following the announcement of its Q3FY25 results. Muthoot Finance’s net profit increased 25.9% YoY to Rs 1,389.2 crore, beating Trendlyne’s Forecaster estimates by 4.4%. Revenue grew 35.9% YoY to Rs 5,189.7 crore during the quarter. 

    During the quarter, the company reported its highest-ever AUM growth of 34% YoY at Rs 1.1 lakh crore. The gold loan segment witnessed remarkable growth of 34% YoY, compared to Q2FY25 (up 28% YoY), driven by higher gold prices and new customer additions. Commenting on this, George Alexander Muthoot, the Managing Director, said, “There is strong demand for gold loans as credit from other sources, including fintech, unsecured, and microfinance lending, has dried up in recent months". 

    Muthoot Finance witnessed a drop in its microfinance (MFI) lending in Q3. The company’s disbursals were down 47% YoY as it remained cautious, given sector challenges. The MFI sector has been facing pressures due to rising bad loans and slower growth. Muthoot’s GNPA (gross non-performing asset) in the microfinance business rose to 2.9% from 1.9% in Q3FY24. However, conditions are expected to improve over the next few quarters as the company moves its focus to improving its collection efficiency as well as the quality of its loan book.

    Going forward, the management maintains its guidance for gold loan growth at 25% YoY in FY25. For FY26, Muthoot Finance projects a 15% growth and expects to surpass the target. 

    Following the company’s earnings announcement, Nuvama upgraded its rating to ‘Buy’ from ‘Reduce’ and raised the target price to Rs 2,550. The brokerage believes the company is well-positioned for sustained growth. It remains bullish due to Muthoot Finance’s consistent performance, supported by rising gold prices. Trendlyne classifies it as a Turnaround Potential stock.

    3. ITC:

    This cigarettes & tobacco products company touched a 52-week low of Rs 396.2 on 20th February. The decline in its stock price came after reports suggested that the government may increase the GST on tobacco products once the compensation cess is removed. Currently, cigarettes and other tobacco products are subject to a 28% GST, along with cess and other levies, bringing the total indirect tax to 53%.

    The government aims to maintain its tax revenue from tobacco products after the compensation cess ends on March 31, 2026, and is not inclined to replace it with another cess. The GST Council's Group of Ministers (GoM) had previously suggested linking the cess to a product’s maximum retail price instead of its sales value. This proposal was later referred back to the fitment committee and the GoM on rate rationalization.

    On February 8, ITC announced its plan to enter the frozen foods and ready-to-cook business by acquiring a 43.8% stake in both ‘Prasuma’ & ‘Meatigo’ for around Rs 300 crore, reportedly. The deal is expected to be completed in over three years. ITC plans to increase its stake to 62.5% in ‘Prasuma’ by April 2027, with the remaining stake to be potentially acquired by June 2028. Hemant Malik, Wholetime Director of ITC, stated, “The deal will enable ITC to develop a portfolio in the frozen, chilled, and ready-to-cook (RTC) segment of the Rs 10,000 crore market, which holds significant growth potential.”

    The Company announced its Q3FY25 results on February 6th. During the quarter, its net profit declined by 7.5% YoY to Rs 4,934.8 crore due to muted demand in FMCG and hikes in prices of key input materials like edible oil, leaf tobacco and wood. Revenue was up by 8.6% YoY. The company’s revenue beat forecaster estimates by 6.9%, due to growth in the cigarettes and agri segment revenue. It appears on a screener for stocks with high FII stock holdings.

    KR Choksey has maintained a ‘Buy’ rating on ITC but lowered its FY26 and FY27 EPS estimates by 6.1% and 7.5%, respectively, due to the hotel business demerger, weak Q3FY25 performance, soft demand, and inflationary pressures. Despite this, the brokerage remains optimistic about ITC’s long-term prospects, thanks to its strong cigarette market share, solid FMCG execution, and rural demand recovery. Following the demerger, the brokerage has adjusted its valuation to 40% of market capitalization with a 20% holding discount, lowering its target price to Rs 494.

    4. ABB India:

    This heavy electrical equipment company has fallen by 2.8% over the past week, despite surpassing the Forecaster estimates for revenue and net profit in its Q4CY24 results. The company's order inflow (OI) declined 14% YoY to Rs 2,700 crore, primarily due to a 30% drop in the motion (motors and drives) segment. This segment benefited from a large data centre order in Q4CY23. However, base orders (with completion timelines of 3-12 months) rose 4%, while the order book stood at Rs 9,400 crore.

    CFO T. Sridhar said, "The market is easing out, which can lead to lower pricing power on new orders.” Sridhar flagged profit margin pressures, “We expect profit margins to settle in the 12-15% range (15.4% in CY24)," he said. 

    Sridhar noted that while order growth was strong earlier, sustaining the same pace may be difficult since the company already has a large number of existing orders. However, he expects private capex to rise after the 2025 budget, with growth driven by sectors like power generation, automotive, food & beverages and data centres.

    ABB India’s EBITDA margin improved to 19.5% (up 440 bps) due to high-margin orders and better capacity utilization. The company appears in a screener of stocks with growing costs YoY from long-term projects.

    ABB’s MD, Sanjeev Sharma, discussed the impact of US tariffs, stating that they could open opportunities for India to expand its role in global trade. While the company has grown its export portfolio, it still accounts for only 10% of its business. The company anticipates exports to contribute positively to India, despite global market fluctuations.

    Post results, ICICI Securities upgraded its rating on ABB India to ‘Hold’ with a target price of Rs 5,302. The brokerage believes the company will benefit from the Centre's capex push in renewables, infrastructure, EVs, and manufacturing. Additionally, its strong distribution network enhances its ability to secure industry orders.

    5. Cipla:

    This pharmaceuticals company has risen 2.1% in the past month in a weak market owing to strong Q3FY25 results, where revenue and net profit grew by 7.5% YoY to Rs 7,294.6 crore and 48.7% YoY to 1,570.5 crore. 

    On Wednesday, the company invested ZAR 900 million (~Rs 424.9 crore) in its subsidiary, Cipla Medpro South Africa Proprietary, for 4.1 crore shares. The company has a strong presence in South Africa and intends to expand its footprint. 

    The drug maker also received final approval from the US FDA for a new drug application (NDA) for Nilotinib Capsules and a Form 483 with two observations from the US FDA following a good manufacturing practices (GMP) inspection at its analytical testing facility in Navi Mumbai. 

    The company’s Q3 revenue and net profit beat Forecaster estimates by 1.9% and 30.4%, respectively. Revenue improved due to increased sales in the Indian, South African, and rest of the world (RoW) markets. However, the US market witnessed a downturn due to Lanreotide supply issues due to temporary lower production at a partner facility. 

    The company’s Indian business grew due to improvements in branded prescriptions, chronic, and trade generics. Meanwhile, reducing inventory and finance costs, combined with launching high-margin products, helped its net profit grow. 

    Speaking on its results, Cipla’s MD and CEO, Umang Vohra, said, “Our Emerging Markets & Europe (EMEU) and One Africa businesses together account for more than 25% of total revenue, similar in size to our US business. In 9MFY25, these markets combined have delivered a strong growth of 15% YoY. Our diversification and backlog of our launch pipeline gives us confidence in a resilient business model.”

    Post results, Axis Direct retains its ‘Buy’ call on Cipla. It has a target price of Rs 1,700 per share, indicating a potential upside of 15.2%. The brokerage believes that the company’s India business will continue to grow, driven by diversification and a strong launch pipeline. However, it expects the US business to remain sluggish due to the continued supply issues of Lanreotide. Axis Direct expects the firm’s revenue to grow at a CAGR of 8.3% over FY25-26.

    Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    20 Feb 2025

    Chart of the Week: US import tariffs trigger a trade war

    By Abdullah Shah

    With US President Donald Trump imposing retaliatory import tariffs and threatening even more (“It’ll be 25% and higher, and it’ll go very substantially higher over a course of a year”)the world is facing a trade war. Global markets have turned volatile and India’s Nifty 50 index has fallen 1.2% over the past month. 

    The ordeal started with President Trump issuing three executive orders on February 1 to impose import tariffs on China, Canada, and Mexico. The US levied a 10% import tariff on all Chinese goods and a 25% duty on imports from Mexico and Canada, effective February 4. However, President Trump delayed the duties on Mexico and Canada for 30 days after reaching deals with them. Trump followed this by imposing another 25% import duty on all steel and aluminium imports, including Canada and Mexico, effective March 12. The duty will also include finished metal products. 

    President Trump has indicated further retaliatory tariffs of 25% on imports of automobiles, expected to be rolled out in April 2025 after saying that the EU and India have  unfair taxes on US automobile exports. Trump is also planning  additional 25% import duty on the pharmaceuticals and semiconductor sectors to promote domestic factories in the US. 

    With reciprocal tariffs dominating headlines, we look at the countries with the highest tariffs on imports from the US in this chart of the week.

    The European Union and India give contrasting responses to the tariffs

    In the Union Budget FY26 meeting, India reduced its average import tariff to 10.7% from 11.7% in response to the US's threat of tariffs on pharmaceutical and automotive products. India has reduced customs duties on bourbon whiskey by 50 percentage points to 100% and levies on high-end motorcycles by 20 percentage points to 30%. 

    A report by Nomura suggests that even with increased US tariffs from 15-20%, the decline in Indian exports to the US would be approximately 3% to 3.5%. The relatively minor fall is attributed to India's efforts to diversify its export markets, enhance value addition, and develop alternative trade routes. S&P Global Ratings also believes India's economy is more oriented towards domestic products and less reliant on exports, further lowering the effects of tariffs.

    The 25% tariffs by the US on steel and aluminium imports will also apply to the European Union (EU) despite the EU signing a free trade agreement with the Biden administration. This is despite European countries like Germany, Ireland, Italy, and France having low import tariffs on US goods due to the US importing a large number of goods from the region. Ireland has an average tariff of 6.5%, while Italy, Germany and France have an import tariff of 2% each. 

    European Commission President Ursula von der Leyen said that the EU will take proportionate countermeasures to protect its interests. EU Trade Commissioner Maroš Šefcovic emphasised the potential for these tariffs to fuel inflation and disrupt global trade. The EU is considering various retaliatory measures, including tariffs on iconic American products and potential legal challenges through the World Trade Organization (WTO).

    These steel and aluminium tariffs, revoking previous agreements that had allowed tariff-free quotas for UK steel exports, also impact the country’s steel industry. These free trade agreements helped the US with lower import tariffs of 3.8% for US goods in the UK. However, the US is the UK's second-largest steel export market, with approximately 2 lakh tonnes of steel, valued at over £400 million, exported annually. The reintroduction of these tariffs will promote domestic steel production in the US but poses a substantial threat to the UK's steel industry, potentially leading to decreased exports and financial losses. 

    China and Canada respond to the US tariffs

    After Trump announced the tariffs, Canada responded on February 3 with President Justin Trudeau imposing a 25% duty on imports of all US goods. This was followed by Mexico’s President Claudia Sheinbaum taking tariff and non-tariff measures in defense of Mexico’s interests. 

    The moves prompted President Trump to hold talks with the two countries and delay the implementation of the tariffs on Mexico and Canada by 30 days. 

    The tariffs will put pressure on consumer prices, contributing to inflation in the US. Federal Reserve officials have expressed concerns that these trade policies could disrupt supply chains and increase costs for businesses and consumers. 

    Speaking on the tariffs on Mexico and Canada, the US National Association of Manufacturers President and CEO Jay Timmons said, “A 25% tariff on Canada and Mexico threatens to destroy the very supply chains that have made US manufacturing more competitive globally. Manufacturers will bear the brunt of these tariffs, undermining our ability to sell our products competitively and putting American jobs at risk.”

    In response to the US levies, the Chinese Finance Ministry announced a 15% tariff on coal and liquefied natural gas and 10% on crude oil, farm equipment, large-displacement vehicles and pickup trucks from the US. While announcing the tariffs, the Finance Ministry stated, “The unilateral imposition of tariffs by the US seriously violates the rules of the World Trade Organization. It is not only unhelpful in solving its own problems but also damages economic and trade cooperation between China and the US.”

    China has also applied export restrictions on critical minerals, such as tungsten, tellurium, ruthenium, molybdenum, and ruthenium-related items.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    20 Feb 2025
    How pessimistic are Indian CEOs after a weak Q3? | Screener: Multibagger stocks that are beating the bears

    How pessimistic are Indian CEOs after a weak Q3? | Screener: Multibagger stocks that are beating the bears

    When it comes to growth predictions, the biggest optimist in the mix is not the investor or the analyst, but the company management. The CEO rides or dies on the basis of how their company performs. So they can't help wearing rose-colored glasses.

    But the Q3 results came out in a pretty bearish market, and have disappointed. Nearly half of the companies announced negative or neutral profit growth. Average revenue growth across the universe is in the low single digits. It's hard to be cheerful in the face of these numbers. 

    We take a closer look at what the management focused on, in this results season's earnings calls. CEOs are battling weak domestic demand, rising trade barriers from a confrontational Trump White House, and a slowing global economy. A rising dollar - as Trump keeps talking up reciprocal tariffs - is not helping.  

    In this week's Analyticks:

    • Mood Tracker: What are the risks and opportunities CEOs are talking about in earnings calls?
    • Screener: Multibagger stocks that are still beating the bear market

    Let's take the temperature.


    It's hot under the collar: CEOs discuss their biggest risks

    The problem? CEOs talk a lot. The solution? Trendlyne's Discover, which allowed me to search for specific comments and phrases across all earnings calls. This tool saved me a lot of time this week. I didn't have to wade through every line of each earnings call, while my eyesight suffered, my family fell apart and my cat escaped. Instead, my cat is happily sunbathing (proof) while I bring you this data.

    When we look at CEO commentary across earnings calls, management is pointing to a challenging economic environment.  

    Nikhil Sohoni, CFO at Blue Star, noted that margins have been impacted across key segments, and "we expect the revival to happen only slowly, over the next year." Some industries like cement saw temporary regional weaknesses, like in South India, where prices were depressed since price revisions happen in December. But in most industries, the twin problems of low demand and rising costs are not expected to resolve by Q4. 

    The twin monsters of Trump tariffs and inflation

    The new US administration has  arrived with the intention to shake things up. President Trump is firing federal workers, letting Elon Musk comb through government databases, and threatening tariffs against major trade partners.

    Joe Biden rarely got a mention from Indian CEOs. But Donald Trump looms large in the discussions, especially with major export players, from electronics to auto. 

    For CEOs, a worry that comes from Trump tariffs is trouble closing deals. Trump has been making threats with long timelines, where tariffs get imposed in March or April this year. K Natarajan, MD of Galaxy Surfactants, noted that some deal talks have frozen in place as a result, with customers saying that they "want to wait and watch" to see what kind of tariffs get implemented.

    The other challenge is in having to realign supply chains. CEOs note that while tariffs will be passed on to customers, companies will have to work to minimize their effects over time. "For the short term, Trump tariffs will have to be passed on to the market," Nikhil Kumar, MD of TD Power says. "In the longer term, we will have to see where we can manufacture where the duties will not apply." 

    Other threats, like inflation and rising debt, were mainly raised by CEOs in response to questions from analysts. Many are counting on inflation and interest rates coming down over the next few quarters, making these less of a threat compared to a trade war.

    CEO commentary suggests that most think that the worst is behind them. Analysts may discount such optimism, but the management is pointing to lower inflation, and indicators showing recovering manufacturing and services activity. Companies are also responding with new product and capacity investments.

    Some industries are also benefiting from growing export markets, despite the broader headwinds. GE Vernova T&D has for instance, seen a rise in large deals from Europe in the energy and utilities sector, as energy transition investments in the EU ramp up.  

    The biggest opportunities in specific industries are getting mentions from multiple CEOs. GLP - weight loss drugs - is one of the biggest, with a stream of generic drugs coming in from Indian pharma as patents start to expire in 2026 in Asia and Africa. The electric vehicles ecosystem has also been a strong deals pipeline for auto and auto component manufacturers, even as tariffs loom.

    But while areas like defence spending still remain high and lucrative, opportunities like large infrastructure projects may be slowing down. "NHAI projects have become competitively very crowded", the MD of Afcons Infrastructure says, "So we are mainly looking into state level proposals now."

    CEOs are hoping that the tax cuts from the Budget will boost domestic demand, and the new RBI leadership will drive interest rate cuts. But for management, uncertainty is the real growth killer. Tariffs now are better than the promise of tariffs later, since the second freezes companies and customers in place. Once the US administration finally drops the hammer, Indian CEOs can make their moves. 


    Screener: Multibagger stocks which are rising in the past quarter

    Beating the bears: Pharma, metals stocks are among the big gainers

    The Indian equity markets have seen a massive sell-off of Rs 63,641.1 crore by foreign investors over the past month after threats of import tariffs from President Donald Trump, resulting in the Nifty 50 falling by 1.5%. In this volatile market, we look at multibagger stocks which have continued their share price growth. This screener shows multibagger stocks rising in the past quarter despite a negative sentiment in the market.

    The screener is dominated by stocks from the pharmaceuticals & biotechnology, general industrials, banking & finance, food, beverages & tobacco, and consumer durables sectors. Most notable stocks in the screener are PG Electroplast, Shakti Pumps (India), Wockhardt, Godfrey Phillips India, BSE, Blue Jet Healthcare, Sarda Energy & Minerals, and Lloyds Metals & Energy. 

    PG Electroplast features in the screener after rising 318.5% in the past year. This consumer electronics company has continued this trend in recent months, rising 24.5% in the past quarter after posting positive results in Q3FY25. Its revenue and net profit grew by 81.6% YoY to Rs 974.9 crore and 106.2% YoY to Rs 39.5 crore, respectively. 

    Higher sales of air conditioners and washing machines contributed to revenue growth. The company’s stock price also surged after signing an agreement with Whirlpool of India on December 24, 2024. PG Electroplast will manufacture some of the stock-keeping units (SKUs) for semi-automatic watching machines for Whirlpool at its facility in Roorkee. 

    Shakti Pumps has risen 189.5% in the last year. This industrial machinery company’s stock price increased by 11.3% in the past quarter, driven by strong Q3FY25 results. Its revenue grew by 31.3% YoY to Rs 652.7 crore on the back of an improvement in sales in the domestic market. On the other hand, net profit increased by 130.2% YoY to Rs 104.1 crore, owing to deferred tax returns during the quarter. 

    The company’s stock price also got a boost after it entered a partnership with ReNew Photovoltaic on February 3 to supply a domestic content requirement (DCR) cell-based solar module worth Rs 1,300 crore. Its board of directors also approved raising Rs 400 crore by issuing equity shares through a qualified institutional placement (QIP) in January.

    You can find some popular screeners here.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    18 Feb 2025
    Five stocks to buy from analysts this week - February 18, 2025

    Five stocks to buy from analysts this week - February 18, 2025

    By Divyansh Pokharna

    1. United Breweries:

    Anand Rathi maintains its ‘Buy’ rating on this breweries & distilleries company with a target price of Rs 2,610, indicating a potential upside of 29%. Telangana recently announced a 15% price hike on beer, following a pause in supply from UB. The company had suspended supplies to Telangana Beverages Corp due to losses from unchanged base prices for two years. The state's price hike now enables the company to resume sales with better margins.

    United Breweries holds a 70% market share in Telangana's beer market, contributing around 15% to its revenue. Analyst Ajay Thakur expects a 2% rise in revenue and a 200 bps improvement in margins due to this price hike.

    United Breweries is focusing on cost-saving initiatives, some of which will incur upfront costs in FY25. Thakur highlights that these efforts are expected to result in annual fixed cost savings of 1.5–3%. Thakur projects a 380 bps expansion in EBITDA margin from these.

    Thakur also expects a strong start to seasonal sales, as reports suggest a hot summer. He said, “Last year, multiple election phases negatively impacted the sales of beer and alcoholic beverages, but this won’t be the case this time, allowing for better capture of seasonal demand.” He has factored in an 11.5% revenue CAGR over FY25-27.

    2. Fortis Healthcare:

    Prabhudas Lilladhar maintains a ‘Buy’ rating on this healthcare facilities company with a target price of Rs 760, indicating an upside potential of 25.8%. The company’s Q3FY25 net profit rose 84.1% YoY to Rs 247.9 crore, aided by a Rs 23.5 crore exceptional gain from the sale of its Richmond Road facility in Bangalore in December 2024. Revenue increased 14.8% YoY to Rs 1,928.3 crore.

    Analysts Param Desai and Sanketa Kohale highlight that the hospital business revenue grew 17% YoY to Rs 1,620 crore, supported by higher occupancy and an improved average revenue per occupied bed (ARPOB). Occupancy rose to 67% from 64% in Q3FY24, while ARPOB increased 10% YoY to Rs 67,100, driven by a favorable case mix and price revisions in February 2024.

    The analysts note that the company plans to add 400 brownfield beds at Fortis Memorial Research Institute, Faridabad, and Noida by FY26. Of its 350 planned greenfield beds in Manesar, 50 are operational, with another 50 expected by March 2025. Management targets 350-400 brownfield bed additions annually for two years. Desai and Kohale expect a CAGR of 13.2% in sales, 19.7% in EBITDA, and 21.7% in net profit over FY25-27.

    3. Eicher Motors:

    Emkay maintains a ‘Buy’ rating on this motorcycle manufacturer with a target price of Rs 6,100. This indicates an upside potential of 29.3%. Eicher Motors’ Q3FY25 net profit grew 17.5% YoY to Rs 1,170.5 crore. Revenue increased 18.7% YoY to Rs 5,261.9 crore, helped by higher two-wheeler and commercial vehicle sales.

    Analysts Chirag Jain, Jaimin Desai and others note the company achieved 17% volume growth in Q3FY25, outperforming the industry, thanks to new product launches like the Battalion Black Edition of the Classic 350 and Hunter 350. Royal Enfield’s domestic motorcycle market share increased to 8%, a 1.1% YoY rise. Eicher Motors also increased brand awareness with targeted marketing spends (~Rs 70 crore), which helped drive demand.

    The analysts highlight that the company expects to reduce discounts and increase prices due to new emission rules (OBD2 Phase B), which require higher manufacturing costs. With strong government capex support, the company is on track to meet its FY25 capex target of Rs 1,000 crore. They expect a CAGR growth of 12.8% in revenue, 13.9% in net profit, and 8.9% in Royal Enfield volumes over FY25-27.

    4. Va Tech Wabag:

    Axis Direct maintains a ‘Buy’ rating on this non-electrical utilities firm with a target price of Rs 1,970. This indicates a potential upside of 51.7%. The company has secured new orders worth over Rs 2,781 crore in Q3FY25, taking its total order book to around Rs 14,200 crore. It also recently won a Rs 3,251 crore consortium order for the Al Haer Independent Sewage Treatment Plant in Saudi Arabia. Analysts Sani Vishe and Shivani More expect the company to surpass its Rs 16,000 crore order book target by the end of FY25.

    The company reported a 15% YoY growth in revenue to Rs 811 crore in Q3. EBITDA margin stood at 12.4%. The company’s management noted that margins were lower during the quarter due to project-specific variations, but expects improvement in the medium term. EBITDA margins are projected to be in the 13-15% range, possibly exceeding the upper limit. They are confident of a stronger performance in Q4, as it is typically the best quarter of the year in terms of performance.

    Vishe and More are upbeat about Va Tech's focus on expanding its share of higher-margin international, industrial, and operations and maintenance (O&M) contracts. They believe the company's strong order book, which provides revenue visibility for the next 3-4 years, particularly from international projects, will help it achieve its targeted margins.

    5. EPL:

    Motilal Oswal reiterates its ‘Buy’ rating on this packaging firm with a target price of Rs 300. This indicates a potential upside of 20.8%. In Q3FY25, the company’s revenue grew 4% YoY to Rs 1,010 crore. EBITDA margin increased by 107 bps to 19.9%, helped by better margins in the Americas and Europe. The company’s management expects these strong margins to continue, supported by demand in Brazil, which is prompting the company to accelerate its capacity expansion in the region.

    Analysts Sumant Kumar, Meet Jain, and Nirvik Saini noted that potential tariffs do not impact the company’s US operations as it manufactures locally and sources laminates from India. If China faces trade restrictions, EPL could gain market share. Additionally, EPL is establishing a beauty & cosmetics manufacturing facility in Thailand to improve delivery speed and localization. The company is targeting a market of 150 crore units annually and plans to expand into Indonesia, Vietnam, and Malaysia.

    The company’s Q3 financials were impacted by currency devaluation in Brazil and Egypt. However, the management expects forex fluctuations to balance out over time, and anticipates some reversal of forex losses in Q4.

    Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

    (You can find all analyst picks here)

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    14 Feb 2025
    Five Interesting Stocks Today - February 14, 2025

    Five Interesting Stocks Today - February 14, 2025

    By Trendlyne Analysis

    1. SBI Cards and Payment Services:

    This finance company rose by over 5% on 13th January and touched a 52-week high of Rs 872 today. The surge in its stock price came after the global brokerage Macquarie upgraded its rating on the stock to ‘Outperform’, as it believes that the company's credit card delinquencies have decreased, indicating better lending choices. Over the past 12 months, the company limited credit to borrowers with higher credit scores. The brokerage has also increased the stock's target price to Rs 1,000.

    Its Q3FY25 net profit declined by 30.2% YoY to Rs 383.2 crore due to tighter regulations on fee income. Revenue was up by 0.5% YoY, primarily due to marginal growth in interest income. The company’s net profit missed forecaster estimates by 8.7%, due to a slower loan growth. It appears on screener for stocks where FIIs & FPIs are increasing their shareholding.

    The company’s Gross Non-Performing Assets (GNPA) slightly decreased to 3.24% during the quarter, down from 3.27% in the previous quarter. However, the gross credit cost rose by 40 bps to 9.4% QoQ. 

    Regarding the increase in credit costs, the company’s CEO & MD, Abhijit Chakravorty, said, “We are at an inflection point in our credit cycle. As we tighten underwriting, portfolio management, and collections, we expect credit costs to moderate. The speed of this will depend on changes in the unsecured lending ecosystem and the economy.”

    According to RBI’s December 2024 data, the company's market share in card spends stood at 15.6%. Girish Budhiraja, Chief Sales & Marketing Officer, stated, "We expect our card spend market share to reach 18-20% in the next 3-4 quarters. We are projecting loan growth of 12-15% over the next 9-12 months. However, our outlook could change in either direction if the credit cost trajectory shifts or the economic mood changes."

    Macquarie forecasts a significant decline in the company’s credit costs over the next two quarters, driven by factors like falling interest rates, better liquidity, and potential tax cuts. The brokerage also points out that the RBI's more lenient approach to unsecured loans could be an added boost. However, it has reduced its earnings projections for FY25-27 by 13-15%, reflecting slower growth in loans, net interest income and fee generation. 

    2. National Aluminium Company:

    This aluminum manufacturer has fallen 7.8% in the past week despite beating Forecaster estimates for revenue and net profit in its Q3FY25 results. The decline comes after US President Trump’s move to set a 25% tariff on steel and aluminum imports without any exemptions. National Aluminium Co’s (NALCO) management noted that these tariffs could put pressure on global aluminum prices, similar to the impact seen in 2018-2020 after similar trade policies during Trump’s first term.

    NALCO announced its Q3FY25 results on February 10, reporting a 39% YoY increase in revenue to Rs 4,662 crore, driven by higher sales realisation in alumina and metal. Net profit surged 2.3X YoY to Rs 1,566 crore, thanks to lower employee benefit expenses, material costs, and finance costs. The company appears in a screener of stocks with book value per share improving over the last two years.

    Chairman & MD Pratap Singh said, “The alumina price trend of $400/tonne in previous years was breached when prices shot up to $800/t in Q3FY25 due to plant shutdowns in Australia. The prices are now correcting, with spot prices falling to $530/t and possibly declining further to the $450-500/t range.” 

    Singh also highlighted that analysts should not get too optimistic about the net profit jump – the decline in employee costs that drove profit higher, he noted, was due to a one-time provision for non-executive performance-related pay (PRP). Going forward, annual employee expenses are expected to stay over Rs 2,000 crore.

    Speaking about capex, Singh said that NALCO is expanding its alumina refinery, increasing capacity by 1 million tonnes per annum (MTPA) from the current 2.1 MTPA. The total capex for this expansion is now Rs 5,677 crore, of which Rs 3,500 crore has already been spent. The refinery is expected to be commissioned by the end of FY26, revised from the earlier target of September 2025.

    Axis Direct has a ‘Buy’ rating on this PSU stock with a target price of Rs 220. The brokerage expects strong alumina realisations to drive another good quarter in Q4FY25. However, with spot prices declining, the impact of lower alumina prices may be seen from Q1FY26 onwards. Additional alumina volumes from the ongoing refinery expansion, however, will help offset some of the impact of lower prices on EBITDA in the future.

    3. FSN E-Commerce Ventures (Nykaa):

    This internet retail company has declined 3% over the past week following the announcement of its Q3FY25 results. Nykaa’s net profit increased 61.4% YoY to Rs 26.1 crore, but missed Forecaster estimates by 29.6%. 

    Revenue rose 26.7% YoY to Rs 2,267.2 crore during the quarter, driven by growth in the beauty & personal care (BPC) and fashion segments. The company’s revenue beat estimates marginally by 0.2%.

    During the quarter, Nykaa’s GMV (gross merchandise value) grew 25% YoY, driven by strong growth in the BPC segment, which contributes the majority of its revenue and has seen an increasing customer base and festive demand. Meanwhile, Nykaa Cosmetics, Kay Beauty, and Dot & Key continued to drive growth with new launches – the company is pushing its own brands hard, including its wakeup makeup line. The fashion segment grew 8% YoY despite a challenging demand environment and intense competition.

    Recently, Shein, the Chinese low-cost fast-fashion giant, re-entered India through a partnership with Reliance Retail. Falguni Nayar, the CEO, underplayed the threat to Nykaa’s market share, saying, “Fashion is a vast industry. Shein operates in just one segment. With 4,000+ brands and more international players entering the market, no single brand can dominate”. 

    But analysts think differently, and believe Shein's re-entry into India could disrupt the country’s fashion market. Nykaa’s fashion vertical, which competes with Myntra, Tata Cliq Fashion, and Ajio, is expected to expand its catalogue with new brand partnerships. 

    Meanwhile, Nykaa continued to expand its retail network, with total stores reaching 221. The company expects to grow its store count to 350 over the next two years. 

    Following the Nykaa’s earnings announcement, Nuvama maintained its ‘Buy’ rating. The brokerage highlights that competition in fashion remains a concern, but profitability improvements in the eB2B segment are encouraging. It expects Nykaa’s beauty segment to remain a key growth driver.

    4. Global Health (Medanta):

    Thishealthcare facilities company surged 10.7% on February 5 following the announcement of itsQ3FY25 results. During the quarter, the company’s net profit rose 15.6% YoY to Rs 142.9 crore in Q3FY25, while revenue grew 13.3% YoY to Rs 943.4 crore. The growth was driven by higher patient volumes, with a 10% increase in footfalls and a 13% rise in In-Patient Department (IPD) admissions.

    The companyreported an Average Revenue Per Occupied Bed (ARPOB) of Rs 61,307, reflecting a marginal 1.2% YoY increase but a 1.3% QoQ decline. Toimprove ARPOB, Medanta is pushing high-value procedures, which contribute to better revenue per patient. 

    Medanta is also improving its payer mix by reducing dependence on lower-paying government schemes and increasing the proportion of insurance and cash patients. Additionally, the companyplans selective tariff hikes, particularly in facilities like Lucknow and Patna, where prices have remained unchanged for several years.

    In Q3 FY25, Medantaadded 34 beds, bringing the total bed additions to 219 for the first nine months of FY25. This has increased the company’s total operational bed capacity to 3,042. The company hassecured a long-term lease for a 110-bed hospital in Ranchi to expand its presence in Jharkhand. Additionally, the 550-bed Noida hospital is set to begin operations within six months. 

    Pankaj Sahni, Group Chief Executive Officer of the companysaid, “We have roughly 1,000 bed additions planned over the next two years. We also have 3 major Greenfield projects underway, comprising approximately 1,600 beds.” These include projects in Mumbai Oshiwara, Pitampura, and Greater Kailash, which are expected to be completed in the next 3 to 4 years.

    Post results, Axis Directmaintains its ‘Buy’ rating on this company, citing optimism about the business recovery, improvements in ARPOB, and capacity expansion. The brokerage expects a CAGR of 21.5% in sales, 18.2% in EBITDA and 18.1% in net profit over FY25-26, with a target price of Rs 1,270 per share.

    5. Power Finance Corporation:

    This financial institution is a value stock, under radar, according to Trendlyne’s DVM score. PFC exhibits high financial strength and is trading at an affordable valuation, demonstrated by its high durability and valuation scores. However, the stock price momentum is weak due to the recent correction in the stock market. Shares of PFC currently trade at a discount of over 35% from its 52-week high.

    In Q3, the company reported a revenue growth of 14% and a net profit growth of 23% on a YoY basis. Its consolidated loan book witnessed a 12% YoY growth, driven by disbursements in the renewable and distribution segments. To further expand its renewable portfolio, it entered into an agreement on January 16 with Japan Bank for International Cooperation for a loan of ~Rs 6,500 crore.

    Foreign currency borrowing makes up 19% of its total borrowings, of which 95% is hedged against currency fluctuations. The remaining 5% unhedged portfolio has come under risk following the recent depreciation of INR. Chairman and MD Parminder Chopra noted that PFC anticipates a loss of Rs 45 crore for every one-rupee depreciation of INR with respect to USD.

    PFC is in the advanced stages of resolving loan defaults totalling around Rs 5,000 crore from the KSK Mahanadi, TRN Energy, and Shiga Energy projects. Once resolved, it expects to release approximately 73% of the allocated provisions—roughly Rs 3,650 crore—which is the capital set aside to cover potential losses should these companies default on their loans.

    During the Q3 earnings call, Chopra said, “We expect these provision reversals to provide sufficient cushion against the impact of rupee depreciation.” The resolution of these defaults is expected to improve PFC’s asset quality, potentially lowering its gross non-performing assets (NPAs) from 2.7% at the end of Q3 to below 2%. 

    Chopra is confident of a strong performance in Q4, driven by disbursements in the renewable portfolio, which will help PFC achieve its guidance of 13-14% annual growth in assets under management for FY25. Motilal Oswal maintains a ‘Buy’ rating on the stock, anticipating a surge in disbursements of 110% YoY in Q4, supported by benign credit costs and the resolution of its stressed assets.

    Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    13 Feb 2025

    Chart of the Week: Stocks across sectors miss analyst estimates by big margins in Q3FY25

    By Abdullah Shah

    The Q3FY25 results season has been under par, with approximately 44% of companies that released their results seeing negative profit growth. In this edition of the chart of the week, we screen for stocks with the highest negative surprises in revenue and net profit during the quarter, according to Forecaster. 

    The negative surprises screener is dominated by stocks from the auto, finance, pharma & biotech, consumer durables, and general industrials sectors. Major stocks in the screener include India Cements, Adani Enterprises, Biocon, BEML, Alembic Pharma, Bosch, CCL Products India, Angel One, Astral, and Bajaj Auto among others.

    The companies in the screener disappointed investors for various reasons. Net profit misses were due to higher costs in raw materials and operations. Revenue underperformed estimates owing to increased competition, pricing pressure and weak demand in the domestic market.

    The auto sector struggled with low demand from the domestic market, leading to missed estimates, while the pharma & biotech stocks saw strong pricing pressure and increased competition. 

    India Cements & Adani Enterprises underperform estimates due to higher input costs

    India Cements has seen the highest Forecaster estimated net profit miss of 198.8% in Q3FY25, while its revenue missed estimates by 4.5%. This comes after the cement & cement products company’s net loss expanded by a steep 26x YoY and revenue declined by 16.8% YoY during the quarter. Rising expenses in raw materials, inventory, employee benefits, finance, power & fuel, and transportation resulted in expanding net loss. Its revenue has also fallen YoY for the past seven consecutive quarters. According to analysts at Motilal Oswal Financial Services, India Cements’ revenue was also hit by lower price realisations in the blended cements segment. 

    Adani Enterprises also features in the screener after its net profit and revenue missed Forecaster estimates by 96.6% and 14.4%, respectively, in Q3FY25. This was a result of the commodity trading & distribution company’s net profit and revenue plunging by 96.9% YoY and 18.5% YoY. Increasing costs were also a factor here – in raw materials, inventory, employee benefits, finance, depreciation & amortisation, and foreign exchange, which drove the decline in net profit. Meanwhile, its revenue decreased owing to a reduction in the integrated resources management (IRM), commercial mining, and road segments. 

    Speaking on the company’s results, its Director and natural resources CEO, Vinay Prakash said, “The IRM business declined due to a good domestic coal availability for customers, resulting in lower sales. We have been exploring ways to tap into newer market segments through initiatives like the IRM portal, an e-portal for the online trading of natural resources.”

    Biocon & Alembic Pharma miss estimates on the back of increasing pricing pressure

    Biocon’sQ3FY25 net profit and revenue missed Forecaster estimates by 80.5% and 2.4%, respectively, after falling 96.2% YoY and 14.7% YoY. The biotech company’s net profit declined due to rising costs in inventory, employee benefits, etc. A reduction in sales from the generics and biosimilars businesses resulted in a degrowth in revenue. The biosimilar business revenue fell due to the company selling its branded generic immunotherapy and nephrology businesses in FY24. 

    However, analysts are positive about the company. Axis Direct believes that Biocon has a strong product line over the next three years, including five new products, like Aspart, Bevacizumab, Denosumab, and Stelara, which are expected to drive growth. It expects the company’s revenue and net profit to grow at a CAGR of 11.7% and 10.2%, respectively, over FY25-26.

    Alembic Pharmaceuticals witnessed its Q3FY25 net profit and revenue missing its Forecaster estimates by 20.5% and 2.5%, respectively. This comes after the pharmaceutical company’s net profit declined due to higher costs in raw materials and employee benefits. Meanwhile, revenue missed estimates due to a reduction in the active pharmaceutical ingredient (API) business. 

    Analysts at KR Choksey believe the company struggled with headwinds in the acute therapy business, which saw seasonal weakness. The API business has also struggled due to pricing headwinds, lower demand from key customers, and heavy competition from low-cost manufacturers. 

    Auto stocks underperform estimates, led by weak demand

    BEML’sQ3FY25 net profit and revenue missed Forecaster estimates by 72.5% and 23.6%, respectively, after decreasing 49.4% YoY and 18.6% YoY. The commercial vehicles company’s net profit fell due to increasing inventory and finance costs. On the other hand, weak demand for commercial vehicles due to muted construction activity led to a decline in revenue. 

    Bajaj Auto is another notable auto stock to feature in the screener, with its net profit and revenue missing Forecaster estimates by 3.1% and 1.4%, respectively in Q3FY25. Higher sales of lower-margin electric vehicles led to this ?-wheeler manufacturer’s net profit missing estimates. Meanwhile, lower demand in the domestic market resulted in revenue underperforming estimates.

    Post results, Rakesh Sharma, Executive Director of Bajaj Auto, stated, “Going forward, we expect the domestic two-wheeler segment growth to be around 6-8%. We plan to continue to build share in the 125cc+ segment through steady expansion of Freedom and leveraging the expanded lineup for Pulsars, KTMs, and Triumphs.”

    Bosch’sQ3FY25 net profit and revenue underperformed Forecaster estimates by 15.9% and 1.2%, respectively. This comes after the auto equipment company’s net profit declined due to higher costs in raw materials, inventory, and employee benefits. However, revenue missed estimates, driven by declining sales of heavy commercial vehicle components. 

    Guruprasad Mudlapur, Managing Director and CTO of Bosch highlighted, “The growth is driven by mobility aftermarket, two-wheeler, power sports and consumer goods businesses. Looking ahead, sustained macro stability, policy support, and consumer liquidity will be critical in maintaining momentum and ensuring broad-based growth across segments.”

    Copy LinkShare onShare on Share on Share on
     
    logo
    The Baseline
    12 Feb 2025, 09:18PM
    The missing piece in India's growth | Screener: Exporters outperforming the Nifty

    The missing piece in India's growth | Screener: Exporters outperforming the Nifty

    By Swapnil Karkare

    It’s February, and summer has officially hit Mumbai. Not that it's ever cold here - I have a drawer full of sweaters that I barely use. Sometimes in December I see a fellow Mumbaiker optimistically wearing their underused woolens, but let's not fool ourselves.

    On the bright side, as the days warm up, I can finally indulge in ice cream. Chocolate’s my go-to flavour. But the tough part is deciding between choco chips and Belgian dark chocolate.

    But why do I have to choose, really? It doesn't have to be 'either-or'; it can be 'and'. That’s what Minister Ashwini Vaishnaw has been saying for India’s growth path: not manufacturing or services, but both. Multiple paths can rapidly grow India's GDP, just as multiple ice-cream scoops can grow my waistline.

    Bloomberg estimates that India can be the GDP growth leader globally by 2028, the way China used to be in the past two decades. WEF President Børge Brende expects India to contribute to 20% of global growth in the coming years, from 15% currently.



    In this week's Analyticks,

    Recipe for growth: India is still missing key pieces as we try to boost the economy

    Screener: Exporters outperforming Nifty with growth in revenue and profit

    India's recipe for growth is missing high-end manufacturing

    A country's growth usually comes with rising complexity. Countries start with simple, low-cost products like clothes, shoes, and commodities. Then they move up to high-tech goods like electronics, electric cars and aircraft, plus advanced services like chip designing, R&D, and AI. They build on their capabilities over time, to move into specialized sectors.

    A good example of how this complexity works is Finland's growth path. Finland historically had a lot of tree cover, so over time they became good at building machines that cut trees. Finnish manufacturers soon developed automated cutting machines, and then became better at making automated machines across different industries. That skill over time, led to Nokia.

    The first Nokia factory was originally a wood pulp plant.

    Similarly China moved from making cheap toys and electronics to becoming a leader in electric cars. South Korea became a global electronics giant, while India’s IT sector grew from call centres to a global tech powerhouse.

    To understand this better, economists use something called the Revealed Comparative Advantage (RCA) index — a fancy way of saying, “What has a country become really good at making and exporting?” If the score for a product is greater than 1, it means the country exports more of that product than the world average, indicating a comparative advantage, and vice versa.

    Where does China score high in 'comparative advantage'?

    By 1999, China already had a strong manufacturing base, excelling in primary (food, beverages, and minerals), low-tech (leather, textile, glassware, furniture, and jewellery) and high-tech products (advanced machines, pharma products and radioactive materials). By 2023, it had shifted from low-value sectors and now dominates high-tech industries.


    India's move from low to medium specialization

    Two decades ago, India had a competitive edge in primary, resource-based (food processing, rubber, wood, and cement), and low-tech industries. In 2023, its scores for these sectors have declined, but remain above 1. But India is getting better at producing medium (auto and auto componenets, synthetic fibers, and appliances) and high-tech products. But scores for the higher-end sectors are still below 1 - we are lagging the global average here.

    The trend shows that India is still great at making things like clothes, shoes, and toys. But we haven't yet moved into more advanced manufacturing like electronics and biotechnology.

    Electronics: From importer to exporter

    Not long ago, India relied on imports for most electronics. Today, it’s becoming an export leader in this space. Electronics exports jumped from $4.5 billion in FY15 to $28.5 billion in FY24 – a stunning 23% CAGR. The secret sauce? A blend of tax cuts, production incentives, and capital support.

    Last year, India registered a 40% increase in mobile phone exports, while China and Vietnam saw declines. India captured nearly 50% of China and Vietnam’s lost mobile exports — a sign of its growing dominance.

    The smartphone production-linked incentive (PLI) scheme played an important role. Giants like Apple, Xiaomi, and Samsung ramped up production in India, with Apple doubling its exports from India. Today, iPhones make up 65% of India’s mobile exports. Dixon Technologies, a key player in PLI, expanded its workforce from 9,000 before the pandemic to 26,000 today, manufacturing products for Motorola, HP, Lenovo, LG, and more.

    “What we’re used to seeing in China is these large mega factories, where thousands of people are working on one campus and live on that campus; we are also trying to do that in India”, says Sunil Vachani, Dixon’s chairman.

    So India has entered the electronics manufacturing space -- but we have yet to move up the value chain, from assembly to design.




    India’s rise in global pharma

    India is the world's largest vaccine maker, producing 60% of global vaccines, and is making waves in biotech research and development. A few companies are leading this front. Zydus for instance, has beat global giants like Novartis and Roche in testing NLP3R inhibitors for amyotrophic lateral sclerosis (ALS) disease. Glenmark’s ISB 2001, a blood cancer drug, could be a cheaper alternative to J&J’s Darzalex, if approved. 

    The government has targeted making this a $300 billion industry by 2030 from $130 billion today, through policies like the PLI, National Biotechnology Development Strategy 2020-2025 and the Bio-E3.

    But there’s also a political angle to this story.

    The US Biosecure Act, which aims to ban federal agencies from purchasing Chinese drugs, is awaiting a decision from the Trump administration. Even though the Act hasn't yet passed the Senate, global companies are already moving their supply chains away from China. This shift presents a significant opportunity for Indian pharmaceutical companies, which already provide 40-50% of generic drugs in the US.

    Not every industry is a winner

    The Indian government has been building support for many promising industries. But today’s factories are quite different from those in the ‘80s and ‘90s. They have more automated machines and robots. The Economist notes that this makes it harder for poor countries to compete in manufacturing.  It also makes it harder for governments to know which industries to help.

    When venturing into new sectors where it lacks experience, India must start small and choose carefully the areas it builds expertise in. Some may not pay off at all. Take semiconductors, for example. India has ambitious manufacturing plans, but most proposed facilities will only assemble chips (low value), not design them (high value). It is also a late entrant to a semiconductor space where many countries are jockeying for supremacy.

    The manufacturing+services strategy gets a boost from GCCs

    The good news? India’s services sector is evolving alongside its manufacturing efforts.India is no longer housing just basic call centres; it's becoming a global hub for Global Capability Centers (GCCs). GCCs work as overseas offices of big companies. They handle tasks like tech development, research, and customer service.

    India is home to 1,700 GCCs, 17% of the global total. This number could rise to 2,200+ in the next few years. Consulting firm Zinnov’s CEO Pari Natarajan, calls Indian GCCs "the nerve centres of global tech advancement".

    GCCs earned over $64 billion in FY24, up from $46 billion in FY23. They are creating a wealth of high-paying, specialised jobs and could generate over 4 lakh jobs this year. Companies are even tapping into smaller cities like Visakhapatnam, Coimbatore, Jaipur, Vadodara, Kochi, and Chandigarh to find talent.

    India faces the difficult challenge of finding jobs quickly for millions of low-skilled and high-skilled workers, which can only be answered with a manufacturing and services combo. The one advantage India has in a difficult global environment of tariffs and competition, is hostility in the US and EU to a rising China. Politics+economics, combined with manufacturing+services, may be India's real advantage in the coming years.


    Screener: Exporters outperforming the Nifty with growth in revenue and profit

    Auto & chemical stocks outperform Nifty 50 after strong profit growth in Q3FY25

    As we near the end of the results season, we look at exporters with the best performance in Q3FY25. This screener shows stocks outperforming the Nifty 50 in month change with YoY growth in revenue and net profit.

    The screener is dominated by stocks from the chemicals & petrochemicals, automobiles & auto components, pharmaceuticals & biotechnology, and textiles apparels & accessories sectors. Major stocks that feature in the screener are UPL, Maruti Suzuki, TVS Motor, Sumitomo Chemical India, Divi’s Laboratories, Epigral, Garware Technical Fibres, and Mahindra & Mahindra.

    UPL surged by 11.3% over the past month, outperforming the Nifty 50 index by 12.8 percentage points after its net profit and revenue grew by 168% YoY and 10.3% YoY, respectively, in Q3FY25. This helped the agrochemicals company’s net profit and revenue to beat Forecaster estimates by 138.8% and 1.2%, respectively. Net profit surged on the back of lower raw materials, finance, and exchange differences on trade receivables. On the other hand, sales growth and rising prices of its products helped the company’s revenue increase.

    Maruti Suzuki also shows up in the screener after its price rose 9.4% over the past month, outperforming the Nifty 50 by 11 percentage points. This comes in response to the cars & utility vehicles manufacturer’s net profit and revenue growing by 16.2% YoY and 15.4% YoY during Q3FY25, helping to surpass Forecaster estimates by 2.1% and 2.9%, respectively. A reduction in inventory costs and a deferred tax return during the quarter helped profit increase, while a recovery in sales in the rural market helped with revenue growth.

    You can find some popular screeners here.

    Signing off this week,

    The Trendlyne Team

    Copy LinkShare onShare on Share on Share on
     
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd